Evidence map›Paper›PMID 40580492›Full record

ReviewVirulence2025

Development of the coronavirus reverse genetic system: Core technology for pathogenesis mechanisms research and vaccine/drug development.

Yue Zhang, Ruifeng Hou, Zhanyong Wei, Jin Yuan, Shaopo Zu

Abstract readReview
In one paragraph

Review in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yue ZhangCollege of Veterinary Medicine, Henan Agricultural University, Zhengzhou, P. R. China.
Ruifeng HouCollege of Veterinary Medicine, Henan Agricultural University, Zhengzhou, P. R. China.
Zhanyong WeiCollege of Veterinary Medicine, Henan Agricultural University, Zhengzhou, P. R. China.
Jin YuanCollege of Veterinary Medicine, Henan Agricultural University, Zhengzhou, P. R. China.
Shaopo ZuCollege of Veterinary Medicine, Henan Agricultural University, Zhengzhou, P. R. China.ORCID 0009-0005-4527-0965

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronaviruses (CoVs) are enveloped, single-stranded, positive-sense RNA viruses that cause respiratory, gastrointestinal, hepatic, and neurological diseases in humans and other animals. In recent years, frequent outbreaks of emerging and re-emerging CoVs have threatened animal and human health. However, an insufficient understanding of the mechanisms underlying CoV pathogenicity and cross-species transmission limits the development of drugs and vaccines against CoVs. Reverse genetic technology is a powerful tool for manipulating the genomes of CoVs and acquiring recombinant viruses, which allows researchers to better understand viral pathogenesis and develop genetically attenuated and marked vaccines and antiviral drugs. However, the large genomes of CoVs and the instability and toxicity of viral sequences in bacteria represent serious obstacles to the development of reverse genetic systems of CoVs. With the development of molecular biological methods, various new construction strategies have emerged. Accordingly, this review summarizes the construction strategies of CoV reverse genetics systems and their applications in studying pathogenesis, cross-species transmission, vaccine development, and drug screening, with the aim of providing an important reference for the prevention and control of CoVs.

Indexed as

CoronavirusReverse GeneticsVaccine DevelopmentAnimalsAntiviral AgentsCOVID-19 VaccinesDrug DevelopmentHumansSARS-CoV-2Viral VaccinesAntiviral AgentsCOVID-19 VaccinesViral Vaccinesantiviral drug-screeningCoronaviruscoronavirus tropisminfectious clonepathogenesisreverse genetic system

Identifiers

PMID40580492
PMCPMC12218529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.